Bolt Biotherapeutics Announces Executive and Board Changes
Ticker: BOLT · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1641281
| Field | Detail |
|---|---|
| Company | Bolt Biotherapeutics, Inc. (BOLT) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, compensation, board-changes
TL;DR
Bolt Bio brings in new CMO, inks exec deals, and grants stock options.
AI Summary
On August 28, 2024, Bolt Biotherapeutics, Inc. announced changes to its board of directors and executive compensation. Specifically, Dr. David J. Earp was appointed as Chief Medical Officer, and the company entered into a new employment agreement with him. Additionally, the company entered into a new employment agreement with Dr. Robert L. Kirk, Chief Scientific Officer, and approved a new stock option grant for him.
Why It Matters
These changes in key leadership roles and compensation structures can signal shifts in the company's strategic direction and its commitment to retaining top talent for future development.
Risk Assessment
Risk Level: medium — Changes in executive roles and compensation can indicate internal shifts or strategic realignments that may impact future performance.
Key Players & Entities
- Bolt Biotherapeutics, Inc. (company) — Registrant
- Dr. David J. Earp (person) — Appointed Chief Medical Officer
- Dr. Robert L. Kirk (person) — Chief Scientific Officer
- August 28, 2024 (date) — Date of earliest event reported
FAQ
What is the effective date of the reported changes?
The earliest event reported is dated August 28, 2024.
Who has been appointed as the new Chief Medical Officer?
Dr. David J. Earp has been appointed as the new Chief Medical Officer.
What other executive officer has a new employment agreement?
Dr. Robert L. Kirk, Chief Scientific Officer, has a new employment agreement.
What type of compensation was approved for Dr. Robert L. Kirk?
A new stock option grant was approved for Dr. Robert L. Kirk.
What is the principal executive office address for Bolt Biotherapeutics, Inc.?
The principal executive offices are located at 900 Chesapeake Drive, Redwood City, California, 94063.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 9.9 · Accepted 2024-09-04 17:38:58
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share BOLT The Nasdaq Global Se
Filing Documents
- d886159d8k.htm (8-K) — 26KB
- 0001193125-24-213225.txt ( ) — 146KB
- bolt-20240828.xsd (EX-101.SCH) — 3KB
- bolt-20240828_lab.xml (EX-101.LAB) — 18KB
- bolt-20240828_pre.xml (EX-101.PRE) — 11KB
- d886159d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Bolt Biotherapeutics, Inc. Date: September 4, 2024 By: /s/ W ILLIAM P. Q UINN William P. Quinn President, Chief Executive Officer and Chief Financial Officer